TY  - JOUR
AU  - Muranen, Taru A
AU  - Morra, Anna
AU  - Khan, Sofia
AU  - Barnes, Daniel R
AU  - Bolla, Manjeet K
AU  - Dennis, Joe
AU  - Keeman, Renske
AU  - Leslie, Goska
AU  - Parsons, Michael T
AU  - Wang, Qin
AU  - Ahearn, Thomas U
AU  - Aittomäki, Kristiina
AU  - Andrulis, Irene L
AU  - Arun, Banu K
AU  - Behrens, Sabine
AU  - Bialkowska, Katarzyna
AU  - Bojesen, Stig E
AU  - Camp, Nicola J
AU  - Chang-Claude, Jenny
AU  - Czene, Kamila
AU  - Devilee, Peter
AU  - Domchek, Susan M
AU  - Dunning, Alison M
AU  - Engel, Christoph
AU  - Evans, D Gareth
AU  - Gago-Dominguez, Manuela
AU  - García-Closas, Montserrat
AU  - Gerdes, Anne-Marie
AU  - Glendon, Gord
AU  - Guénel, Pascal
AU  - Hahnen, Eric
AU  - Hamann, Ute
AU  - Hanson, Helen
AU  - Hooning, Maartje J
AU  - Hoppe, Reiner
AU  - Izatt, Louise
AU  - Jakubowska, Anna
AU  - James, Paul A
AU  - Kristensen, Vessela N
AU  - Lalloo, Fiona
AU  - Lindeman, Geoffrey J
AU  - Mannermaa, Arto
AU  - Margolin, Sara
AU  - Neuhausen, Susan L
AU  - Newman, William G
AU  - Peterlongo, Paolo
AU  - Phillips, Kelly-Anne
AU  - Pujana, Miquel Angel
AU  - Rantala, Johanna
AU  - Rønlund, Karina
AU  - Saloustros, Emmanouil
AU  - Schmutzler, Rita K
AU  - Schneeweiss, Andreas
AU  - Singer, Christian F
AU  - Suvanto, Maija
AU  - Tan, Yen Yen
AU  - Teixeira, Manuel R
AU  - Thomassen, Mads
AU  - Tischkowitz, Marc
AU  - Tripathi, Vishakha
AU  - Wappenschmidt, Barbara
AU  - Zhao, Emily
AU  - Easton, Douglas F
AU  - Antoniou, Antonis C
AU  - Chenevix-Trench, Georgia
AU  - Pharoah, Paul D P
AU  - Schmidt, Marjanka K
AU  - Blomqvist, Carl
AU  - Nevanlinna, Heli
TI  - PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.
JO  - npj Breast cancer
VL  - 9
IS  - 1
SN  - 2374-4677
CY  - London
PB  - Nature Publ. Group
M1  - DKFZ-2023-00982
SP  - 37
PY  - 2023
AB  - We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC). PREDICT for estrogen receptor (ER)-negative breast cancer had modest discrimination for BRCA1 carrier patients overall (Gönen </td><td width="150">
AB  -  Heller unbiased concordance 0.65 in CIMBA, 0.64 in BCAC), but it distinguished clearly the high-mortality group from lower risk categories. In an analysis of low to high risk categories by PREDICT score percentiles, the observed mortality was consistently lower than the expected mortality, but the confidence intervals always included the calibration slope. Altogether, our results encourage the use of the PREDICT ER-negative model in management of breast cancer patients with germline BRCA1 variants. For the PREDICT ER-positive model, the discrimination was slightly lower in BRCA2 variant carriers (concordance 0.60 in CIMBA, 0.65 in BCAC). Especially, inclusion of the tumor grade distorted the prognostic estimates. The breast cancer mortality of BRCA2 carriers was underestimated at the low end of the PREDICT score distribution, whereas at the high end, the mortality was overestimated. These data suggest that BRCA2 status should also be taken into consideration with tumor characteristics, when estimating the prognosis of ER-positive breast cancer patients.
LB  - PUB:(DE-HGF)16
C6  - pmid:37173335
C2  - pmc:PMC10182045
DO  - DOI:10.1038/s41523-023-00546-x
UR  - https://inrepo02.dkfz.de/record/276076
ER  -